[go: up one dir, main page]

MX2011007194A - Combinacion de un derivado ciclosporina y nucleosidos para tratar virus de hepatitis c (vhc). - Google Patents

Combinacion de un derivado ciclosporina y nucleosidos para tratar virus de hepatitis c (vhc).

Info

Publication number
MX2011007194A
MX2011007194A MX2011007194A MX2011007194A MX2011007194A MX 2011007194 A MX2011007194 A MX 2011007194A MX 2011007194 A MX2011007194 A MX 2011007194A MX 2011007194 A MX2011007194 A MX 2011007194A MX 2011007194 A MX2011007194 A MX 2011007194A
Authority
MX
Mexico
Prior art keywords
nucleosides
combination
treating hcv
cyclosporine derivative
cyclosporine
Prior art date
Application number
MX2011007194A
Other languages
English (en)
Inventor
Samuel Earl Hopkins
Original Assignee
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scynexis Inc filed Critical Scynexis Inc
Publication of MX2011007194A publication Critical patent/MX2011007194A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Esta invención se refiere a combinaciones que comprenden 3-[(3)-2-(N,N-Dimetilamino o una sal, solvato o hidrato farmacéuticamente aceptable de la misma; y ciertos análogos de nucleosido, y su uso en el tratamiento de virus de hepatitis C.
MX2011007194A 2009-01-07 2010-01-07 Combinacion de un derivado ciclosporina y nucleosidos para tratar virus de hepatitis c (vhc). MX2011007194A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14306209P 2009-01-07 2009-01-07
US15602609P 2009-02-27 2009-02-27
US25723109P 2009-11-02 2009-11-02
PCT/US2010/020323 WO2010080878A1 (en) 2009-01-07 2010-01-07 Combination of a cyclosporine derivative and nucleosides for treating hcv

Publications (1)

Publication Number Publication Date
MX2011007194A true MX2011007194A (es) 2013-07-12

Family

ID=42084646

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007194A MX2011007194A (es) 2009-01-07 2010-01-07 Combinacion de un derivado ciclosporina y nucleosidos para tratar virus de hepatitis c (vhc).

Country Status (11)

Country Link
US (1) US20100227801A1 (es)
EP (1) EP2385833A1 (es)
JP (1) JP2012514606A (es)
CN (1) CN102271688A (es)
AU (1) AU2010203660A1 (es)
BR (1) BRPI1007027A2 (es)
CA (1) CA2748792A1 (es)
IL (1) IL213862A0 (es)
MX (1) MX2011007194A (es)
RU (1) RU2011127079A (es)
WO (1) WO2010080878A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1802650E (pt) * 2004-10-01 2011-12-30 Scynexis Inc Derivados da ciclosporina 3-éter e 3-tioéter substituída para o tratamento e prevenção da infecção de hepatite c
ATE498630T1 (de) * 2005-09-30 2011-03-15 Scynexis Inc Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion
ES2361635T3 (es) 2006-05-19 2011-06-20 Scynexis, Inc. Ciclosporinas para el tratamiento y prevención de trastornos oculares.
KR101089112B1 (ko) * 2006-06-02 2011-12-06 피씨 제스띠옹 에스.아.에스. 활성 전자 관리
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2010002428A2 (en) 2008-06-06 2010-01-07 Scynexis, Inc. Novel macrocyclic peptides
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US8716263B2 (en) * 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
CA2748389A1 (en) * 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
MX2012011171A (es) 2010-03-31 2013-02-01 Gilead Pharmasset Llc Fosforamidatos de nucleosido.
JP6069215B2 (ja) 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー 化合物
SG11201400664WA (en) 2011-09-16 2014-04-28 Gilead Pharmassett Llc Methods for treating hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US20140212491A1 (en) 2013-01-31 2014-07-31 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
WO2014197400A1 (en) * 2013-06-04 2014-12-11 Gilead Pharmasset Llc Preventing and treating recurrence of hcv infection after liver transplant
EP3038601B1 (en) 2013-08-27 2020-04-08 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
WO2015164812A1 (en) * 2014-04-24 2015-10-29 Cocrystal Pharma, Inc. 2' -disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
ES2987605T3 (es) * 2018-12-14 2024-11-15 Waterstone Pharmaceuticals Wuhan Co Ltd Maleato de SCY-635 y usos del mismo en medicina
US12226446B2 (en) * 2019-10-11 2025-02-18 Waterstone Pharmaceuticals(Wuhan) Co., Ltd. WS-635 uses thereof in medicine
CN112154151B (zh) * 2020-06-04 2025-04-29 中美华世通生物医药科技(武汉)股份有限公司 治疗或预防冠状病毒科感染
US20250009777A1 (en) * 2021-11-12 2025-01-09 National University Corporation Hokkaido University Antiviral agent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2604620T5 (pl) * 2003-05-30 2024-10-14 Gilead Pharmasset Llc Zmodyfikowane fluorowane analogi nukleozydu
NZ567262A (en) * 2005-09-30 2011-12-22 Scynexis Inc Cyclosporin derivatives and their use for the treatment and prevention of hepatitis C infection
JP4979710B2 (ja) * 2005-12-09 2012-07-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗ウイルスヌクレオシド

Also Published As

Publication number Publication date
AU2010203660A1 (en) 2011-07-28
EP2385833A1 (en) 2011-11-16
BRPI1007027A2 (pt) 2019-09-24
WO2010080878A1 (en) 2010-07-15
CA2748792A1 (en) 2010-07-15
US20100227801A1 (en) 2010-09-09
IL213862A0 (en) 2011-07-31
CN102271688A (zh) 2011-12-07
RU2011127079A (ru) 2013-02-20
AU2010203660A2 (en) 2011-09-29
JP2012514606A (ja) 2012-06-28

Similar Documents

Publication Publication Date Title
MX2011007194A (es) Combinacion de un derivado ciclosporina y nucleosidos para tratar virus de hepatitis c (vhc).
MX2011007364A (es) Derivados de fosforamidato de compuestos de nuecleosido de guanosina para tratamiento de infecciones virales.
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
WO2011123645A3 (en) Nucleoside phosphoramidates
AU2018256602A1 (en) Functionalized benzamide derivatives as antiviral agents against hbv infection
TN2013000421A1 (en) 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
PH12013502033A1 (en) Pyrimidine derivatives for the treatment of viral infections
MX2012011222A (es) Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales.
ZA201901061B (en) 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
GEP20247600B (en) B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
PH12012501216A1 (en) Hcv combination therapy
IL195025A (en) History of compressed indolubenzazepine with cyclopropyl and pharmaceuticals containing them as an anti-hcv drug
MD4403B1 (ro) Compuşi antivirali în bază de dihidroxiizocromen-naftoimidazoli condensaţi
MX2010005355A (es) Derivados de indol sustituidos con 3-aminosulfonilo y metodos de uso de los mismos.
PH12014500724A1 (en) Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication
MX2014003180A (es) Metodos para tratar vhc.
IL195272A0 (en) Methods and compositions for the treatment of viral infections
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
MX2013011411A (es) Tratamiento para infeccion por el virus de hepatitis b solo o en combinacion con el virus de hepatitis delta y enfermedades hepaticas asociadas.
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
IN2012MN02896A (es)
PH12015502589A1 (en) 4`-azido, 3`-deoxy-3`-fluoro substituted nucleoside derivatives
WO2011056630A3 (en) Small molecule inhibitors of hepatitis c virus
MX2014014878A (es) Combinacion de agentes terapueticos para tratar infeccion por el virus de la hepatitis c (hcv).
PH12012501303A1 (en) Compositions and methods for treating hepatitis b virus infection

Legal Events

Date Code Title Description
FA Abandonment or withdrawal